A $40 million longevity fund just bankrolled a gene therapy with three months of safety data and zero regulatory approval. It is already for sale.
The therapy is a follistatin plasmid injected into abdominal fat. The fund is Immortal Dragons, headquartered in Singapore. The sale is underway at clinics in Honduras and Mexico, outside the reach of the FDA, the EMA, and any formal adverse event reporting system. This is not a clinical trial with regulatory oversight. It is a commercial transaction backed by a preprint and a biohacker's Instagram Reel.
The stakes are immediate. The data shows a statistically significant spike in LDL cholesterol. The next trial adds a VEGF component that carries its own risks of vascular leakage. No long-term safety data exists. If a single serious adverse event hits, the entire parallel market could collapse overnight. Or it could force the FDA into a confrontation it has so far avoided.
A single shot, a supraphysiological spike, and an LDL problem
The therapy, developed by Minicircle Inc., delivers the follistatin 344 gene via a polyethyleneimine (PEI) complexed plasmid. Patients receive a single subcutaneous injection of 50 µg into abdominal fat. The gene then drives production of follistatin, a protein that inhibits myostatin and other TGF-beta family members, with the goal of increasing muscle mass and reducing frailty.
The preprint published by Minicircle reports data from 43 adult volunteers, age 23 to 88, median 46. At three months post-injection, serum follistatin rose from a baseline mean of 8.58 ng/ml to 24.03 ng/ml, a value the authors themselves describe as "largely supraphysiological." That is a more than twofold increase. It is not subtle.
The body composition changes were real. Fat-free mass increased by a mean of 1.96 lbs, with one outlier gaining 12.15 lbs. Body fat percentage dropped by a mean of 0.87%. Both results were statistically significant. Markers of inflammation, high-sensitivity C-reactive protein and homocysteine, trended toward improvement.
Then there is the lipid panel. The preprint reports "a large, statistically significant increase in low-density lipoprotein (LDL) that was largely conserved across groups." That sentence, buried in the results, is the one that should stop every prospective patient cold. An LDL spike in a therapy marketed for longevity is not a footnote. It is a cardiovascular risk factor staring you in the face at the three-month mark, with no data on whether it persists, worsens, or resolves.
Three months. That is the entire safety window. No independent replication exists. Every author on the preprint except the administering clinician, Glenn C. Terry, is a Minicircle employee. The trial was sponsored by Minicircle. The data is real. The lens is singular.
Próspera ZEDE: the loophole that makes the sale possible
The trial was conducted at GARM Clinic in Próspera ZEDE, Honduras, a special economic zone with its own regulatory framework. Próspera ZEDE operates under Honduran ZEDE law, which grants it significant autonomy from national regulations. For a gene therapy developer, that autonomy is the product. No FDA IND application. No EMA marketing authorization. No requirement to report adverse events to a national health authority.
Unlimited Bio, a company led by CEO Ivan Morgunov, has now taken that model further. Morgunov told MIT Technology Review that Unlimited Bio's therapies are already accessible at clinics in Honduras and Mexico. The company is running a separate trial with 12 to 15 volunteers covering their own costs, testing two experimental gene therapies simultaneously.
Dave Asprey, the prominent biohacker, posted an Instagram Reel after receiving one of the treatments in Mexico. "I'm just upgrading my system for a little while to reduce my age and reduce my vascular risk," Asprey said. The video features Eterna's CEO describing the therapy as helping "with vascular health systemically."
The biohacker-to-clinic pipeline is now fully operational. A preprint drops. A fund invests. An influencer posts. A clinic in a regulatory gray zone takes payment. No regulator reviews the data. No ethics board outside the zone has jurisdiction. The patient signs a consent form and becomes a data point, or not.
The $40 million double-down: a dual-gene trial with no safety net
Immortal Dragons is not backing away. It is doubling down. Unlimited Bio has registered a Phase 1/2a clinical trial on ClinicalTrials.gov under the identifier NCT07443826. The CALM-AF-AI trial is an open-label, sequential dose-escalation study enrolling approximately 12 participants aged 45 to 75 at GARM Clinic in Roatán, Honduras.
This trial combines two gene therapies: AAV9-delivered follistatin and a VEGF plasmid. The VEGF component is the sharper edge. VEGF promotes blood vessel growth, which carries a known risk of vascular leakage, off-target angiogenesis, and inflammatory responses. Combining it with a therapy that already shows an LDL spike is not conservative medicine. It is a bet that the mechanisms are independent and the risks additive rather than synergistic.
Holly Fernandez Lynch, a lawyer and medical ethicist at the University of Pennsylvania, told New Scientist that "it will be impossible to draw firm conclusions from such a small study, and the trial certainly won't reveal anything about longevity." She is correct. The trial is too small to detect rare adverse events and too short to assess longevity. But it is large enough to generate headlines and small enough to slip through regulatory cracks.
The fund's calculus appears straightforward: get human data fast, build a narrative around body composition and epigenetic age clocks, and scale access through clinics in permissive jurisdictions. The risk is that the first serious adverse event arrives before the second trial reads out.
The LDL signal is a ticking clock
The chain of cause and effect here is specific and falsifiable. The Minicircle preprint confirms the LDL spike is statistically significant and conserved across groups. LDL is a causal risk factor for atherosclerotic cardiovascular disease. A therapy that raises LDL in a population seeking longevity is a therapy that may shorten lifespan in the very dimension it claims to extend.
Patients paying out of pocket in Honduras are not enrolled in a pharmacovigilance system. If a 62-year-old with subclinical atherosclerosis receives this therapy and has a myocardial infarction six months later, no one will attribute it. No one will report it. No one will know if it is the first of many.
The dual-gene trial compounds this risk. Adding VEGF to follistatin is not additive in a simple way. VEGF can increase vascular permeability. An inflammatory response at the injection site or systemically could trigger a cascade that the three-month safety window from the monotherapy preprint does not capture. The CALM-AF-AI trial's 12 participants are not enough to detect a 1-in-100 adverse event. They are enough to generate a 1-in-12 catastrophe that makes headlines.
The regulatory asymmetry is the business model. Próspera ZEDE exists because regulatory arbitrage is valuable. Unlimited Bio and Immortal Dragons are not breaking U.S. law. They are simply operating where U.S. law does not reach. The FDA has authority over drugs marketed in interstate commerce in the United States, not over plasmid injections administered in Roatán. But the FDA also has a mandate to protect U.S. patients, and U.S. patients are traveling to receive these therapies. The agency will face pressure to act.
The prediction: a serious adverse event within 24 months
I predict that within 12 to 24 months, at least one serious adverse event will be reported from these unapproved follistatin or dual-gene therapy trials. The most likely form is a cardiovascular complication, given the LDL signal, or an off-target inflammatory response to the VEGF component. When that happens, three things will follow in sequence.
First, the FDA will issue a public warning. This is the lowest-cost, highest-impact move the agency can make. It does not require enforcement action in Honduras. It requires only a statement that puts U.S. patients and referring physicians on notice. The FDA's recent peptide compounding crackdown shows the agency is willing to use public warnings as a tool when it cannot directly regulate.
Second, the biohacker community will fracture. At least one major influencer who has promoted or received these therapies will publicly distance themselves. The asymmetry is simple: promoting an unapproved gene therapy generates engagement and revenue. Being associated with a patient death generates liability and reputational damage. The second a serious adverse event is documented, the risk-reward calculus inverts for anyone with a platform to protect.
Third, Immortal Dragons will face a binary choice. Pull backing from Unlimited Bio and absorb the loss, or double down on a more regulated trial with independent oversight. The fund's $40 million is not infinite. A single high-profile adverse event could freeze the pipeline of patients willing to travel and pay. The rational move is to pivot toward a trial structure that the FDA or EMA might eventually recognize. The question is whether the fund's managers will be rational under pressure.
The quiet winner in this scenario is the regulated longevity sector. Life Biosciences, co-founded by Harvard biologist David Sinclair, recently received FDA permission to begin a clinical study of its gene therapy for partial epigenetic reprogramming. That is the contrast that matters. When the unapproved parallel market hits its first crisis, the clinics with FDA-cleared trials will gain what no amount of biohacker marketing can buy: regulatory contrast and patient trust. The market will bifurcate. Capital and patients will flow toward the regulated tier.
What would prove me wrong? A clean safety readout from the CALM-AF-AI trial with no serious adverse events and a sustained, favorable body composition signal at 12 months. That outcome would strengthen the parallel market's narrative and attract more capital. I assign that outcome a lower probability, not because the biology is impossible, but because the sample sizes are too small to rule out rare events and the LDL signal is already waving a red flag.
The calculus is brutally simple
If you are a patient considering these therapies, you are making a bet with no safety net. The data is a single preprint. The regulatory oversight is absent. The adverse event reporting system does not exist. The LDL spike is real and its long-term significance is unknown. You are paying to become an experiment, and if something goes wrong, you are on your own.
If you are an investor, the only durable moat in longevity medicine is regulatory approval. The parallel market in Honduras can generate headlines and early revenue. It cannot generate the kind of data that insurers, hospital systems, and mass-market patients require. The first serious adverse event will be a market-defining moment. The smart capital is already positioned behind FDA-cleared trials.
The clock is ticking
The $40 million fund bankrolled a therapy with three months of safety data, a statistically significant LDL spike, and zero regulatory approval. It is already for sale. The dual-gene trial is enrolling. The biohackers are posting. The clinics are collecting payment.
Sometime in the next 12 to 24 months, a patient will have a serious adverse event. When that happens, the question is not whether this parallel market survives intact. It is whether the damage is contained to a single clinic in Honduras or whether it triggers a regulatory and reputational cascade that reshapes the entire longevity field. The only people who should be comfortable with that uncertainty are the ones who have no money and no health on the line.
